期刊
DERMATOLOGIC SURGERY
卷 35, 期 9, 页码 1349-1354出版社
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1524-4725.2009.01240.x
关键词
-
资金
- The National Health Service
BACKGROUND Mohs micrographic surgery (MMS) is recognized globally as the criterion standard for high-risk basal cell carcinoma (BCC). The main advantage of MMS over conventional surgery is the chance of complete tumor removal, but it is also thought, based on experience, to be tissue sparing. OBJECTIVE To determine whether MMS leaves smaller surgical defects than standard surgery. METHODS AND MATERIALS This was a randomized trial involving 30 patients with a clinical diagnosis of BCC. Patients were randomly assigned to MMS or standard surgery. In the standard surgery group the BCCs were excised with 4-mm margins. In the MMS group, tumors were excised with 2-mm margins and subsequent stages of MMS until the tumor was completely removed. An observer unaware of the treatment allocation calculated the defect size. The main outcome measure was defect size in mm(2). RESULTS The median area of the surgical defects in the MMS group was 116.6 mm(2), versus 187.7 mm(2) in the standard surgery group (95% confidence interval for difference=61-126, p <.001). CONCLUSIONS This is the first randomized trial demonstrating that MMS is a tissue-sparing treatment. Trial registration: http://www.clinicaltrials.gov Identifier: NCT00571363. The authors have indicated no significant interest with commercial supporters.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据